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Aims/Introduction: To evaluate the differences in the results of 75-g oral glucose tol-
erance tests (OGTTs) according to gestational age in Japan.
Materials and Methods: In this prospective cohort study, 2,578 pregnant women
were divided into three categories based on their gestational age during the 75-g OGTT:
<14 weeks’ gestation, 14–23 weeks’ gestation and 24–32 weeks’ gestation. The association
between gestational age and the results of the 75-g OGTT were evaluated using multivari-
able analysis.
Results: Early gestational age was associated with high fasting plasma glucose levels at
the time of the 75-g OGTT, and low corresponding 1-h and 2-h plasma glucose levels.
Compared with women with a gestational age of 24–32 weeks, women who had under-
gone the 75-g OGTT at <14 weeks’ gestation had significantly higher odds of gestational
diabetes mellitus diagnosis based on the currently used criteria in Japan (adjusted odds
ratio 1.42, 95% confidence interval 1.07–1.90).
Conclusions: The results of the 75-g OGTT varied by gestational age. The use of the
same 75-g OGTT cut-off values for the diagnosis of gestational diabetes mellitus, regardless
of gestational age, might lead to increases in the prevalence of gestational diabetes melli-
tus diagnosis in Japan.
INTRODUCTION
Gestational diabetes mellitus (GDM) is a common complication
during pregnancy, and it is a risk factor for adverse perinatal
outcomes1–3. However, the diagnostic criteria for GDM vary
across countries. The Hyperglycemia and Adverse Pregnancy
Outcome study showed continuous relationships between carry-
ing out a 75-g oral glucose tolerance test (OGTT) at 24–
32 weeks’ gestation and perinatal outcomes4. Based on the
results of the Hyperglycemia and Adverse Pregnancy Outcome
study, the International Association of Diabetes and Pregnancy
Study Groups (IADPSG) published the diagnostic criteria for
GDM in 20105. At <24 weeks’ gestation, the IADPSG does not
recommend carrying out a 75-g OGTT due to insufficient data
on the association between 75-g OGTTs and perinatal out-
comes6. Alternatively, fasting plasma glucose (PG) is used to
diagnose GDM at <24 weeks’ gestation. At 24–28 weeks’ gesta-
tion, GDM is diagnosed based on a 75-g OGTT5. The Japan
Society of Obstetrics and Gynecology (JSOG) recommends that
GDM screening be carried out for all pregnant women at
≤28 weeks’ gestation, including those in the first trimester ofReceived 14 January 2019; revised 6 March 2019; accepted 15 March 2019
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pregnancy, and that a 75-g OGTT be carried out regardless of
gestational age to diagnose GDM, in Japan7–10.
The IADPSG defines GDM as a fasting PG level of 92–
125 mg/dL at <24 weeks’ gestation5. This cut-off fasting PG
value is extrapolated from that at 24–28 weeks’ gestation11. In
Japan, since June 2010, the JSOG has been confirming the pres-
ence of GDM using the following three criteria during 75-g
OGTTs: fasting PG level 92–125 mg/dL; 1-h PG level
≥180 mg/dL; and 2-h PG level ≥153 mg/dL, regardless of the
gestational age9,10. This means that the IADPSG criteria for
GDM at 24–28 weeks’ gestation are applied to other gestational
ages in Japan.
However, there is a lack of sufficient evidence justifying the
application of the same 75-g OGTT cut-off values for GDM
diagnosis, regardless of gestational age. Furthermore, the results
of previous studies focusing on the differences in the PG levels
or 75-g OGTT results across gestational ages are inconsistent12–
15. If the results of 75-g OGTTs vary across gestational ages,
the likelihood of GDM diagnosis would differ. However, few
studies have investigated this16. The present study was carried
out to evaluate the differences in the results of 75-g OGTTs, in
terms of fasting PG levels, 1-h PG, 2-h PG levels and GDM
diagnosis, by gestational age, in Japan.
METHODS
Study design and participants
The present study was carried out as part of the Japan
Assessment of Gestational Diabetes Mellitus Screening (JAGS)
trial – a prospective cohort study. The JAGS trial was carried
out between 2001 and 2004 in Japan. The primary aims of
the JAGS trial were to examine the prevalence of GDM and
investigate the GDM screening rates in Japan. The ethics
committees of all the hospitals described in the supporting
information approved the study protocol. Written informed
consent was obtained from all participants. The study was
planned such that participants would undergo 75-g OGTTs at
both <24 weeks’ gestation and ≥24 weeks’ gestation. Partici-
pants with hyperemesis gravidarum symptoms did not
undergo 75-g OGTTs regardless of the degree of hyperemesis
gravidarum. Participants and medical staff were not blinded
to the results of the 75-g OGTTs. When the JAGS trial was
carried out, GDM was diagnosed when two or more of the
following values during a 75-g OGTT were met, regardless of
the gestational age: fasting PG level ≥100 mg/dL; 1-h PG level
≥180 mg/dL; and 2-h PG level ≥150 mg/dL – namely, the
1984 JSOG criteria8. Details of the JAGS trial have been
described previously17.
In the present study, only the results of the initial 75-g
OGTT (i.e., a 75-g OGTT at <24 weeks’ gestation) were ana-
lyzed for participants who had undergone the 75-g OGTT
twice. This was because the results of the second 75-g OGTT
(i.e., a 75-g OGTT at ≥24 weeks’ gestation) were only obtained
from the participants who were not diagnosed with GDM
based on the 1984 JSOG criteria at <24 weeks’ gestation.
Data collection
Classification of gestational age at 75-g OGTT
Data on the gestational week at the time the 75-g OGTT was
carried out were collected from medical records. Participants
who had undergone a 75-g OGTT at <24 weeks’ gestation were
subdivided into two categories: (i) <14 weeks’ gestation (the
first trimester); and (ii) 14–23 weeks’ gestation. Among partici-
pants who had undergone a 75-g OGTT at ≥24 weeks’ gesta-
tion, those who had undergone a 75-g OGTT at ≥33 weeks’
gestation were excluded, as the number of participants was too
small to be analyzed. Therefore, participants were classified into
three categories based on their gestational age during the 75-g
OGTT (i.e., <14 weeks’ gestation, 14–23 weeks’ gestation and
24–32 weeks’ gestation).
75-g OGTT and definition of GDM diagnosis
The outcomes in the present study were the PG levels during
the 75-g OGTT, and GDM diagnosis. After an overnight fast,
blood was drawn from patients’ veins. SRL, Inc, Tokyo, Japan
– a subcontractor – carried out all blood sample measurements.
The 75-g OGTT results were collected as continuous variables
and were used to diagnose GDM. When the levels of fasting
PG, and 1-h and 2-h PG during a 75-g OGTT were treated as
categorical variables, 92–125 mg/dL, ≥180 mg/dL and
≥153 mg/dL, respectively, were treated as the outcomes, consid-
ering their clinical significance.
In the present study, GDM was defined based on several cri-
teria, such as the 1984 JSOG criteria, 2010 JSOG criteria and
2010 IADPSG criteria. The 1984 JSOG criteria were used until
June 2010 in Japan. After the completion of the JAGS trial in
2004, both the 2010 JSOG criteria and 2010 IADPSG criteria
were published5,9. Therefore, we redefined GDM based on the
2010 JSOG criteria and 2010 IADPSG criteria in the present
study. GDM, based on the 2010 JSOG criteria, was defined
when at least one of the following three values during a 75-g
OGTT, regardless of the gestational age, was met: fasting PG
level of 92-125 mg/dL, 1-h PG level ≥180 mg/dL and 2-h PG
level ≥153 mg/dL10. As per the 2010 IADPSG criteria, GDM is
defined by only a fasting PG level of 92–125 mg/dL, but not
by 1-h and 2-h PG at <24 weeks’ gestation. At 24–28 weeks’
gestation, GDM was also defined when at least one of the
following three values during a 75-g OGTT was met: fasting
PG level of 92–125 mg/dL, 1-h PG level ≥180 mg/dL and 2-h
PG level ≥153 mg/dL. At ≥28 weeks’ gestation, GDM was not
defined in the 2010 IADPSG criteria5. Therefore, when GDM
diagnosis – confirmed based on the 2010 IADPSG criteria –
was treated as an outcome, participants who had undergone a
75-g OGTT at 24–32 weeks’ gestation were restricted to those
who had undergone a 75-g OGTT at 24–28 weeks’ gestation.
Other variables used in this study
All background data were obtained from patients’ medical
records, including maternal age, parity, family history of dia-
betes mellitus, month at 75-g OGTT, bodyweight (BW) at
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delivery, delivery week and infant birthweight. A family history
of diabetes mellitus was defined as the presence of a second-
degree relative with diabetes mellitus. The seasons during which
the 75-g OGTTs were carried out were: spring (March, April
or May), summer (June, July or August), fall (September, Octo-
ber or November) and winter (December, January or February).
Self-reported maternal height and pre-pregnancy BW were also
obtained from medical records. Pre-pregnancy body mass index
was calculated as pre-pregnancy BW in kilograms / (height in
meters)2. Gestational weight gain was calculated as follows: BW
at delivery – pre-pregnancy BW.
Statistical analysis
We applied the general linear model to evaluate the associations
between gestational age at 75-g OGTT (i.e., <14 weeks’ gesta-
tion, 14–23 weeks’ gestation and 24–32 weeks’ gestation) and
the corresponding PG levels as continuous variables. In the
analyses of the associations between gestational age at 75-g
OGTT and the corresponding PG levels as categorical variables
(i.e., fasting PG level of 92–125 mg/dL, 1-h PG level ≥180 mg/
dL and 2-h PG level ≥153 mg/dL), we used a multiple logistic
regression model to calculate the odds ratio (OR). We also
applied a multiple logistic regression model to evaluate the
association between gestational age and GDM diagnosis based
on the 1984 JSOG criteria, 2010 JSOG criteria and 2010
IADPSG criteria. Details on the statistical analyses are described
in the supporting information.
RESULTS
Maternal and neonatal characteristics of the study participants
Figure 1 shows the flow chart of study participant inclusion. Of
the 2,993 study participants, cases of twin pregnancies (18
women), triplet pregnancies (one woman), abortions (16
women) and overt diabetes mellitus in pregnancy – defined as
a fasting PG level ≥126 mg/dL (6 women) – and those with
missing data on the gestational week at the time of the 75-g
OGTT (328 women) were excluded. In addition, women who
had undergone a 75-g OGTT at ≥32 weeks’ gestation (44
women) and those with improbable values (i.e., 0 mg/dL) in
the 75-g OGTT (2 women) were also excluded. Finally, 2,578
women were analyzed in the present study.
Table 1 shows the maternal and neonatal characteristics of
the study participants. The numbers of women who had under-
gone a 75-g OGTT at <14, 14–23 and 24–32 weeks’ gestation
were 970, 690 and 918, respectively. Table 2 shows the results
of the 75-g OGTT of the study participants. The percentages
and numbers of GDM cases based on the 1984 JSOG criteria
and 2010 JSOG criteria were 2.4% (61 women) and 10.1% (261
women), respectively. Of the 2,357 women who had undergone
a 75-g OGTT at ≤28 weeks’ gestation, the percentage (number)
Participants who had undergone a 75-g OGTT at <24 weeks' gestation and/or ≥24 weeks' gestation (n = 2,624)
Participants who consented to participate in this study between 2001 and 2004 (n = 2,993)
Excluded for the following reasons (n = 369)
·  Twin pregnancies (n = 18)
·  Triplet pregnancies (n = 1)
·  Abortion (n = l 6)
·  Overt diabetes in pregnancy, defined as fasting plasma glucose level ≥ 126 mg/dL  (n = 6)
·  Missing data on the gestational week at a 75-g OGTT (n = 328)
Excluded for the following reasons (n = 46)
·  Participants who had undergone a 75-g OGTT at >32 weeks' gestation (n = 44)
·  Improbable values in the 75-g OGTT (n = 2)
Participants who were analyzed (n = 2,578)
Gestational age at 75-g OGTT
·  At <14 weeks' gestation (n = 970)
·  At 14–23 weeks' gestation (n = 690)
·  At 24-32 weeks' gestation (n = 918)
Figure 1 | Flow diagram of study participant inclusion. OGTT, oral glucose tolerance test.
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of GDM cases based on the 2010 IADPSG criteria was 6.3%
(149 women).
Differences in the PG levels during a 75-g OGTT and GDM
diagnosis based on the 1984 JSOG criteria and 2010 JSOG
criteria according to gestational age at 75-g OGTT
Table 3 shows the differences in the results of the 75-g OGTTs
and GDM diagnosis based on the 1984 JSOG criteria and 2010
JSOG criteria across gestational ages, at ≤32 weeks’ gestation.
When the PG level in each 75-g OGTT was treated as a con-
tinuous variable, the earlier the gestational age at 75-g OGTT,
the higher the fasting PG level (P-value for trend <0.0001). In
contrast, the earlier the gestational age at 75-g OGTT, the lower
the 1-h and 2-h PG levels (P-values for trend were <0.0001
and 0.005, respectively).
When each PG value in the 75-g OGTT was treated as a cat-
egorical variable, the earlier the gestational age at 75-g OGTT,
the higher the adjusted OR of fasting PG levels of 92–125 mg/
dL (P-value for trend = 0.001). The linear associations between
gestational age and 1-h PG levels ≥180 mg/dL or 2-h PG levels
≥153 mg/dL were not statistically significant (P-values for trend
were 0.9 and 0.5, respectively).
The differences in the diagnosis of GDM based on the 1984
JSOG criteria, by gestational age, were not statistically signifi-
cant. Women who had undergone a 75-g OGTT at <14 weeks’
gestation had significantly higher odds of GDM diagnosis based
on the 2010 JSOG criteria than those who had undergone a
75-g OGTT at 24–32 weeks’ gestation. The adjusted OR for
GDM diagnosis based on the 2010 JSOG criteria was 1.25
(95% confidence interval 1.07–1.46).
Differences in the fasting PG levels during a 75-g OGTT and
GDM diagnosis based on the 2010 IADPSG criteria according
to gestational age at 75-g OGTT
Table 4 shows the differences in the fasting PG levels at 75-g
OGTT and GDM diagnosis based on the 2010 IADPSG crite-
ria, by gestational age, at ≤28 weeks’ gestation. The results per-
taining to the differences in the fasting PG levels as continuous
variables or categorical variables, according to gestational age,
were similar to the results observed in women who had under-
gone a 75-g OGTT at ≤32 weeks’ gestation. The earlier the ges-
tational age, the lower the adjusted OR for GDM diagnosis
based on the 2010 IADPSG criteria (P-value for trend = 0.002).
Women whose fasting PG levels were examined at <14 and 14-
23 weeks’ gestation had significantly lower odds of GDM diag-
nosis based on the 2010 IADPSG criteria than those who had
undergone a 75-g OGTT at 24–28 weeks’ gestation, with
adjusted ORs of 0.80 (95% confidence interval 0.66–0.97) and
0.65 (95% confidence interval 0.51–0.82), respectively.
DISCUSSION
To the best of our knowledge, this is the first study to show
the difference in the prevalence of GDM diagnosis based on
several diagnostic criteria in Japan by gestational age.
Participants who had undergone a 75-g OGTT at <14 weeks’
gestation had significantly higher odds of GDM diagnosis based
on the 2010 JSOG criteria than those who had undergone the
test at 24–32 weeks’ gestation. In contrast, the differences in
the prevalence of GDM diagnosis based on the 1984 JSOG cri-
teria, by gestational age, were not statistically significant. These
results indicate that the implementation of a 75-g OGTT at
<14 weeks’ gestation might increase the prevalence of GDM,
based on the currently used criteria in Japan.
Participants in whom the fasting PG levels during a 75-g
OGTT were examined at <14 weeks’ and 14–23 weeks’ gesta-
tion had significantly lower odds of GDM diagnosis based on
the 2010 IADPSG criteria than those who had undergone the
test at 24–28 weeks’ gestation. Therefore, the prevalence of
GDM, especially at <24 weeks’ gestation, might decrease if the
2010 IADPSG criteria are adopted in Japan.
The findings of the present study pertaining to the differ-
ences in the fasting PG levels during a 75-g OGTT, by gesta-
tional age, are similar to those of previous studies. Although
the underlying mechanism is unclear, Mills et al.14 reported
that fasting PG levels decrease during pregnancy. They also
showed that a decline in the fasting PG levels begins in the first
trimester14. Hagiwara et al.15 showed that the fasting PG level
in pregnant women with a median gestational age of 13 weeks
at GDM diagnosis was higher than that in those with a median
gestational age of 29 weeks at GDM diagnosis, in Japan. How-
ever, the results of several other studies are not consistent with
the present findings12,13. Siegmund et al.12 reported that fasting
PG levels did not significantly change during pregnancy. Froslie
et al.13 showed that the fasting PG levels at 30–32 weeks’ gesta-
tion were higher than that those at 14–16 weeks’ gestation.
These differences could be attributed to differences in the sam-
ple size, ethnicity and other unmeasured confounding factors.
Women who had undergone a 75-g OGTT at <14 weeks’
gestation had higher odds of GDM diagnosis based on the
2010 JSOG criteria than those who had undergone the test at
24–32 weeks’ gestation; this could be attributed to the high
fasting PG levels rather than the 1-h or 2-h PG levels. In the
present study, women whose fasting PG levels were measured
at <14 weeks’ gestation had higher odds of having levels of
92–125 mg/dL than those in whom the measurement was car-
ried out at 24–32 weeks’ gestation. Therefore, the use of the
same cut-off fasting PG value for GDM diagnosis, regardless of
gestational age, might increase the odds of GDM diagnosis
based on the 2010 JSOG criteria. Opinions on the cut-off fast-
ing PG value for GDM diagnosis at <24 weeks’ gestation are
conflicting. The IADPSG stated that at <24 weeks’ gestation,
GDM is diagnosed when the fasting PG level is 92–125 mg/
dL5. Riskin-Mashiah et al. also proposed that the same cut-off
fasting PG value of 92–125 mg/dL could be used for GDM
diagnosis throughout pregnancy18. However, Cosson et al. pro-
posed that the cut-off fasting PG value for GDM diagnosis
at <24 weeks’ gestation was 100–125 mg/dL, rather than 92–
125 mg/dL19.
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Table 3 | Differences in the plasma glucose levels during a 75-g oral glucose tolerance test and gestational diabetes mellitus diagnosis based on
the 1984 Japan Society of Obstetrics and Gynecology criteria and 2010 Japan Society of Obstetrics and Gynecology criteria according to gestational
age at 75-g oral glucose tolerance test
Outcomes Gestational age at 75-g OGTT (n = 2,578) P-value for
trend
<14 weeks’
gestation (n = 970)
14–23 weeks’
gestation (n = 690)
24-32 weeks’
gestation (n = 918)













1-h PG (mg/dL) -7.3 (-10.0 to -4.7)
<0.0001
-7.2 (-10.1 to -4.3)
<0.0001
Reference <0.0001
2-h PG (mg/dL) -3.2 (-5.5 to -0.9)
0.006









1-h PG (mg/dL) -7.1 (-9.6 to -4.5)
<0.0001
-8.1 (-10.9 to -5.3)
<0.0001
Reference <0.0001
2-h PG (mg/dL) -2.8 (-5.0 to -0.6)
0.01
-3.0 (-5.5 to -0.6)
0.02
Reference 0.005


































































†Crude. ‡Adjusted by maternal age, pre-pregnancy body mass index, parity (primipara or not), family history of diabetes mellitus and season at 75-g
oral glucose tolerance test (OGTT). CI, confidence interval; GDM, gestational diabetes mellitus based on the 1984 Japan Society of Obstetrics and
Gynecology criteria and 2010 Japan Society of Obstetrics and Gynecology criteria; JSOG, Japan Society of Obstetrics and Gynecology; OR, odds ratio;
PG, plasma glucose.
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The implementation of a 75-g OGTT at <14 or 14–
23 weeks’ gestation was associated with low 1-h and 2-h PG
levels compared with those observed in 75-g OGTTs carried
out at 24–28 weeks’ gestation. This finding was consistent with
those of previous studies. Froslie et al.13 showed that the 2-h
PG level during a 75-g OGTT carried out at 14–16 weeks’ ges-
tation was lower than that observed at 30–32 weeks’ gestation.
Hagiwara et al.15 also showed that both the 1-h and 2-h PG
levels during a 75-g OGTT in pregnant women with a median
gestational age of 13 weeks at GDM diagnosis were lower than
those in women with a median gestational age of 29 weeks at
GDM diagnosis. Siegmund et al.12 reported that both 1-h and
2-h PG levels do not significantly change during pregnancy.
One reason for the inconsistency in the findings could be varia-
tions in the sample size. An increase in maternal insulin resis-
tance might be the reason for high 1-h and 2-h PG levels
during a 75-g OGTT at 24–32 weeks’ gestation20. However, the
associations between gestational age at 75-g OGTT and the
presence of corresponding 1-h PG levels ≥180 mg/dL or 2-h
PG levels ≥153 mg/dL were not statistically significant in the
present study. There is a lack of studies focusing on the associ-
ation between the presence of 1-h PG levels ≥180 mg/dL or 2-
h PG levels ≥153 mg/dL during a 75-g OGTT at <24 weeks’
gestation and perinatal outcomes. Therefore, the clinical signifi-
cance of the differences in the 1-h and 2-h PG levels during a
75-g OGTT, at different gestational ages, should be considered
based on further studies investigating the association between
changes in the 1-h PG and 2-h PG levels at 75-g OGTT during
pregnancy and perinatal outcomes.
The present study had several limitations. First, the perinatal
outcomes associated with GDM, which was diagnosed at differ-
ent gestational ages, could not be evaluated, because we did not
collect enough data on adverse maternal and neonatal out-
comes in this study. Therefore, the present study could not
identify the cut-off fasting PG value for GDM diagnosis at
<24 weeks’ gestation. Second, the present study did not obtain
enough data for discussions to be held on the justification of
the implementation of a 75-g OGTT to diagnose GDM at
<24 weeks’ gestation. The European Board and College of
Obstetrics and Gynaecology proposed screening for overt dia-
betes, rather than GDM using fasting PG or glycated hemoglo-
bin levels, or a random PG level at <24 weeks’ gestation21. The
American Diabetes Association also recommends the perfor-
mance of a test for undiagnosed diabetes mellitus, rather than
GDM at <24 weeks’ gestation. The American Diabetes Associa-
tion proposed the criteria for the diagnosis of diabetes mellitus
Table 4 | Differences in the fasting plasma glucose levels during a 75-g oral glucose tolerance test and gestational diabetes mellitus diagnosis
based on the 2010 International Association of Diabetes and Pregnancy Study Groups criteria according to gestational age at 75-g oral glucose
tolerance test
Outcomes Gestational age at 75-g OGTT (n = 2,357) P-value for
trend
<14 weeks’
gestation (n = 970)
14–23 weeks’
gestation (n = 690)
24–28 weeks’
gestation (n = 697)


















































†Crude. ‡Adjusted by maternal age, pre-pregnancy body-mass index, parity (primipara or not), family history of diabetes mellitus, and season at 75-g
oral glucose tolerance test (OGTT). CI, confidence interval; GDM, gestational diabetes mellitus based on the 2010 International Association of Dia-
betes and Pregnancy Study Groups criteria; IADPSG, International Association of Diabetes and Pregnancy Study Groups; OGTT, oral glucose tolerance
test; OR, odds ratio; PG, plasma glucose.
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using fasting PG levels or a 75-g OGTT, or glycated hemoglo-
bin or random PG measurements at <24 weeks’ gestation21,22.
In the European Board and College of Obstetrics and Gynae-
cology and American Diabetes Association recommendations,
GDM is not defined at <24 weeks’ gestation21,22. It is not clear
if GDM diagnosis and intervention initiation at <24 weeks’ ges-
tation can improve perinatal outcomes23,24. Third, data on the
levels of glycated hemoglobin – which are used to diagnose
overt diabetes in pregnancy – were not collected in the present
study. Therefore, the degree of the exclusion of study partici-
pants due to the presence of overt diabetes in pregnancy might
be insufficient.
In conclusion, the fasting PG, and 1-h and 2-h PG levels at
75-g OGTT differed by gestational age. The likelihood of GDM
diagnosis based on the 2010 JSOG criteria and 2010 IADPSG
criteria also differed by gestational age. Healthcare providers
should be aware that the implementation of a 75-g OGTT at
<14 weeks’ gestation was associated with a higher odds of
GDM being diagnosed based on the 2010 JSOG criteria in
Japan. Further studies are required to clarify the association
between the performance of a 75-g OGTT at <24 weeks’ gesta-
tion and perinatal outcomes. In addition, there is a need for
studies that evaluate the benefit of GDM diagnosis and
intervention initiation at <24 weeks’ gestation, and justify the
application of a 75-g OGTT at <24 weeks’ gestation.
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